These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6100571)

  • 1. Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.
    Ninomiya Y; Ohsawa C; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
    Virology; 1984 Apr; 134(2):269-76. PubMed ID: 6100571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.
    Ninomiya Y; Shimma N; Ishitsuka H
    Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410.
    Ishitsuka H; Ninomiya YT; Ohsawa C; Fujiu M; Suhara Y
    Antimicrob Agents Chemother; 1982 Oct; 22(4):617-21. PubMed ID: 6295261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of rhinovirus resistant to an antiviral chalcone.
    Ahmad AL; Dowsett AB; Tyrrell DA
    Antiviral Res; 1987 Aug; 8(1):27-39. PubMed ID: 2825590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
    Dewindt B; van Eemeren K; Andries K
    Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of drug resistance to new antirhinovirus agents.
    Ishitsuka H; Ninomiya Y; Suhara Y
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():11-8. PubMed ID: 3025150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime.
    Ninomiya Y; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
    Antimicrob Agents Chemother; 1985 Apr; 27(4):595-9. PubMed ID: 2988431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410.
    Yasin SR; al-Nakib W; Tyrrell DA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):963-6. PubMed ID: 2168152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the parameters of binding of R 61837 to human rhinovirus 9 and immunobiochemical evidence of capsid-stabilizing activity of the compound.
    Moeremans M; De Raeymaeker M; Daneels G; De Brabander M; Aerts F; Janssen C; Andries K
    Antimicrob Agents Chemother; 1992 Feb; 36(2):417-24. PubMed ID: 1318682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers.
    Phillpotts RJ; Higgins PG; Willman JS; Tyrrell DA; Lenox-Smith I
    J Antimicrob Chemother; 1984 Oct; 14(4):403-9. PubMed ID: 6094423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of rhinovirus-soluble ICAM-1 complexes and conformational changes in the virion.
    Hoover-Litty H; Greve JM
    J Virol; 1993 Jan; 67(1):390-7. PubMed ID: 8093221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Determinants of Human Rhinovirus Infection, Assembly, and Conformational Stability at Capsid Protein Interfaces.
    Valiente L; López-Argüello S; Rodríguez-Huete A; Valbuena A; Mateu MG
    J Virol; 2022 Dec; 96(23):e0084022. PubMed ID: 36374110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.
    Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC
    J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
    Fox MP; McKinlay MA; Diana GD; Dutko FJ
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.
    Pevear DC; Fancher MJ; Felock PJ; Rossmann MG; Miller MS; Diana G; Treasurywala AM; McKinlay MA; Dutko FJ
    J Virol; 1989 May; 63(5):2002-7. PubMed ID: 2539499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity.
    Rosenwirth B; Oren DA; Arnold E; Kis ZL; Eggers HJ
    Antiviral Res; 1995 Jan; 26(1):65-82. PubMed ID: 7741522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanical stiffening of human rhinovirus by cavity-filling antiviral drugs.
    Valbuena A; Rodríguez-Huete A; Mateu MG
    Nanoscale; 2018 Jan; 10(3):1440-1452. PubMed ID: 29302674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.
    Oren DA; Zhang A; Nesvadba H; Rosenwirth B; Arnold E
    J Mol Biol; 1996 May; 259(1):120-34. PubMed ID: 8648640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computer simulation study of the binding of an antiviral agent to a sensitive and a resistant human rhinovirus.
    Lybrand TP; McCammon JA
    J Comput Aided Mol Des; 1989 Jan; 2(4):259-66. PubMed ID: 2541225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers.
    Al-Nakib W; Higgins PG; Barrow I; Tyrrell DA; Lenox-Smith I; Ishitsuka H
    J Antimicrob Chemother; 1987 Dec; 20(6):887-92. PubMed ID: 3326874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.